Today it was announced by the Accelerated Access Collaborative (AAC) that Roche Diagnostics tests for suspected pre-eclampsia and heart attack have been recognized as ‘transformative’ and have been selected among only seven Rapid Uptake Products for the NHS.
Following the Government’s response to the Accelerated Access Review, the AAC are bringing together senior leadership from the Government, the NHS, and the life sciences industry to drive the uptake and adoption of innovation in the NHS, identifying and supporting the innovations that will be most transformative for patients.
Both diagnostic tests have been previously assessed and recommended by the National Institute for Health and Care Excellence (NICE) for use in clinical practice.
The Roche Elecsys immunoassay sFlt-1/PlGF ratio test, used with standard clinical assessment and subsequent clinical follow-up, is recommended to help rule-out pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.
The Elecsys Troponin T high‑sensitive assay is recommended for the early rule out of non‑ST‑segment‑elevation myocardial infarction (NSTEMI) or heart attack, in people presenting to an emergency department with chest pain and suspected acute coronary syndrome.
Both are simple blood tests that can help clinicians quickly decide on the right course of action for patients and their families. The tests also have the potential to alleviate pressure on NHS resources by supporting clinical decision making and focusing efforts where they are most needed.
We are delighted that our diagnostic tests for suspected heart attack and pre-eclampsia have been identified as transformative products for rapid uptake.
We put patients and our healthcare delivery customers at the heart of everything we do and both tests can support more timely and effective diagnosis for patients with potentially life-threatening conditions.
We passionately believe in the wide-reaching value of diagnostics and their power to transform healthcare, and are hopeful that many other such tests that could benefit patients while enabling more efficient use of NHS resources will be introduced across the healthcare system in the near future.”
Geoff Twist, Managing Director of Roche Diagnostics Limited
The AAC has identified 7 high-potential products with a full evidence base already available to the NHS, but with less than expected uptake.
These products will now benefit from a joined-up system of support so that innovations that have been shown to be both clinically and cost-effective to the NHS as well as meeting its priorities can be rapidly introduced and scaled within the health service.